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Abstract 
A simple, sensitive an isocratic RP-HPLC method for the estimation of  Metformin Hydrochloride 
(MET) and Glipizide (GPZ) in combined dosage form using Inertsil C8 column (250×4.6 mm, 5 µ) in an 
isocratic mode with mobile phase comprising  Acetonitrile: Water (70:30) & one drop of Triethylamine. The 
flow rate was 1.0 ml/min and effluent was monitored at 222 nm. The retention times were found to be 3.40 
min for MET and 4.44 min for GPZ. The assay exhibited a linear dynamic range of 100-500 µg/ml of MET 
and 1-5 µg/mL for GPZ .The calibration curves were linear (r = 0.9985 for MET and r = 0.9955 for GPZ) over 
the entire linear range. Recovery was found to be 99.94 % + .17 for MET and 99.61 % + 0.89 for GPZ. % RSD 
of system precision were observed 0.0429 for MET & 0.7212 for GPZ.  
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1. Introduction 
Metformin Hydrochloride (MET) is the first-
line drug of choice for the treatment of type 2 
diabetes, particularly in overweight and obese people 
and those with normal kidney function. Chemically it 
is N,N-dimethylimidodicarbonimidic diamide. 
Metformin hydrochloride (Fig.1) is a white crystalline 
powder that is odour and has a slightly bitter taste and 
hygroscopic, freely soluble in water, slightly soluble 
in alcohol and practically insoluble in acetone, ether 
and chloroform. Metformin improves hyperglycemia 
primarily through its suppression of hepatic glucose 
production (hepatic gluconeogenesis). The "average" 
person with type 2 diabetes has three times the normal 
rate of gluconeogenesis; metformin treatment reduces 
this by over one third. Metformin activates AMP-
activated protein kinase (AMPK), a liver enzyme that 
plays an important role in insulin signaling, whole 
body energy balance, and the metabolism of glucose 
and fats; activation of AMPK is required for 
metformin's inhibitory effect on the production of 
glucose by liver cells. Research published in 2008 
further elucidated metformin's mechanism of action, 
showing that activation of AMPK is required for an 
increase in the expression of SHP, which in turn 
inhibits the expression of the hepatic gluconeogenic 
genes PEPCK and Glc-6-Pase. Glipizide (GPZ) is 
type 2 diabetes mellitus drug. Chemically it is N-(4-
[N (cyclohexylcarbamoyl) sulfamoyl] phenethyl)-5-
methylpyrazine-2-carboxamide. It is whitish, odorless 
powder, which is water solubility-37.mg/ml .insoluble 
in alcohol, soluble in 0.1N NaOH, freely soluble in 
dimethylformamide. Glipizide (Fig.2) is an oral 
medium-to-long acting anti-diabetic drug from the 
sulfonylurea class. It is classified as a second 
generation sulfonylurea, which means that it 
undergoes enterohepatic circulation. The structure on 
the R2 group is a much larger cyclo or aromatic group 
compared to the 1st generation sulfonylureas. This 
leads to a once a day dosing that is much less than the 
first generation, about 100 fold. Mechanism of action 
is produced by blocking potassium channels in the 
beta cells of the islets of Langerhans. By partially 
blocking the potassium channels, it will increase the 
time the cell spends in the calcium release stage of 
cell signaling leading to an increase in calcium. The 
increase in calcium will initiate more insulin release 
from each beta cell.  
The analytical chemistry hence has challenge 
in developing the methods for their analysis with the 
help of number of analytical techniques, which are 
available for the estimation of the drugs and their 
combination. literature survey
2-6,13
 was carried out 
that there are few methods reported for estimation of 
selected drugs singly, however, no stability indicating 
assay method has been reported for estimation of 
MET and GPZ drugs in combined dosage form. 
Market survey revealed that the selected drug MET & 
GPZ is available commercially as combination in 
tablet dosage form and It is used in dibeties. The 
present work is undertaken with an objective to 
develop economical, simple, precise, accurate and 
reproducible stability indicating method for 
estimation of these antidiabetic drugs in their 
combined dosage form.  
Fig 1: Structure of Metformin Hydrochloride   
 
 
 
 
Fig 2: Structure of Glipizide                                              
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2. Methods and Materials1,7,11 
2.1 Chemicals and Reagents 
All the solvents and chemicals used were of 
HPLC and analytical grade. Mili Q water and 0.45 
µm Teflon filter was used throughout the 
experimental work. The gift drug samples of MET 
and GPZ were provided by Cipla Pharma Ltd. 
(Mumbai, India). Chemicals and Reagents Used are 
Hydrogen Peroxide 30%, Ortho-Phosphoric acid, 
Concentrated Hydrochloric Acid, Potassium 
Dihydrogen Orthophosphate, Sodium Hydroxide 
Pellets, Acetonitrile, Water, Methanol.                               
2.2 Instrument 
The chromatographic separation performed 
using Jasco HPLC System with UV detector, model 
2080.31. Software used to monitor was Borwin and 
Quaternary pump is applied. Analytical balance is 
used, Make Sartorious (Model AB - 20.04). pH meter  
was also used, Labindia Make, Model pH System 
362. 
2.3 Preparation of Mobile Phase 
Acetonitrile (HPLC Grade) and Water 
(HPLC Grade) in the ratio of 60:40 was prepared.1 
drop of Triethylamine was added in that .pH was 
made up to the 3.0 Then resulting solution was 
filtered through 0.45μ. filter and degassed using 
sonicator. That solution was used as mobile phase.  
2.4 Preparation of diluent:  
Methanol of HPLC grade was selected as 
common solvent for preparation of stock solution and 
developing spectral characteristics of drugs, further 
dilutions from stock solutions were made in the 
mixture of Acetonitrile and Water in the ratio 70:30. 
2.5 Selection of Analytical Wavelength 
The standard solution of MET and GPZ was 
scanned over the range of 200 nm to 400 nm 
wavelengths. The common wavelength of absorption 
was found to be 222 nm. So the wavelength selected 
for the determination of MET and GPZ was 222nm. 
figure3. 
2.6 Analysis of Physical Laboratory Mixture 
2.6.1 Preparation of Standard Stock Solution  
An accurately weighed quantity of MET 
working standard about 10.0 mg and GPZworking 
standard about 10 mg were transferred separately into 
10.0 mL volumetric flask. About 5.0 mL of methanol 
(HPLC Grade) was added to the volumetric flask and 
sonicated to dissolve the drug. The solution was 
cooled to the room temperature and made up to the 
mark with methanol (HPLC Grade) which gave the 
final concentrations of 1000 g/mL and 1000 g/mL for 
MET and GPZ respectively. Take 0.05mL of GPZ 
and 5.0 mL of MET from stock solution of GPZ and 
MET respectively in a 10 mL volumetric flask and 
make up the volume up to the mark with mobile 
phase to gate 5 μg/mL GPZ. & 500 μg/mL MET. 
2.7 Analysis of Marketed Formulation 
2.7.1 Preparation of Sample Solution 
Take the powder weight of tablet equivalent 
to 500 mg. of MET in 100 mL of volumetric flask and 
add sufficient mobile phase and sonicate it for 15 
min. Make up the volume up to the mark with mobile 
phase and filter it with 0.24μ fillter to get 5000mg/mL 
and 1000 μg/mL of MET and GPZ respectively . Take 
0.05mL of GPZ and 25.0mL of MET from above 
solution of GPZ and MET respectively in a 10.0 mL 
volumetric flask and make up the volume up to the 
mark with mobile phase to gate 5 μg/mL GPZ. & 500 
μg/mL MET.  
The results are shown in Figure7 & discuss 
in the table3. 
2.8 Optimization of Chromatographic Condition 
for Estimation of Drugs 
The mobile phase was allowed to equilibrate 
with stationary phase until steady baseline was 
obtained. The standard solution containing mixture of 
MET & GPZ was run and different individual 
solvents as well as combinations of solvents have 
been tried to get a good separation and stable peak. 
Each mobile phase was filtered through 0.45 µm 
Teflon filter. 
  Finally, the optimal composition of the 
mobile phase, Acetonitrile:Water (70:30) & one drop 
triethylamine was selected. It gave high resolution of 
MET and GPZ with minimal tailing.  
2.9 Caliberation Curves for MET & GPZ 
Weigh accurately 10 mg of Metformin 
Hydrochloride in 10.0mL methanol and 10 mg of 
Glipizide in 10.0 ml of methanol standard in a 
10.0mL volumetric flask and dissolve by sonication 
in sufficient mobile phase then make up the volume 
by mobile phase to prepare 1000 μg/mL stock 
solution. The mobile phase was allowed to equilibrate 
with the stationary phase until steady baseline was 
obtained. The series of concentrations from 1-5 
μg/mL of Glipizide, 100-500 μg/ml of Metformin 
Hydrochloride std. solutions were injected and peak 
area was recorded.  
2.10 System Suitability Test 
System suitability is a pharmacopoeial 
requirement and is used to verify, whether the 
resolution and reproducibility of the chromatographic 
system are adequate for analysis to be done. The tests 
were performed by collecting data from five replicate 
injections of standard solutions. An accurately 
weighed quantity of MET working standard about 
10.0 mg and GPZ working standard about 10.0 mg 
were transferred separately into 10.0 mL volumetric 
flask. About 5.0 mL of Methanol (HPLC Grade) was 
added to the volumetric flask and sonicated to 
dissolve the drug. The solution was cooled to the 
room temperature and made up to the mark with 
Methanol (HPLC Grade) which gave the final 
concentrations of 1000 g/ml and 1000 g/ml for MET 
and GPZ respectively.  
2.11 Validation Parameters
8-9
 
1. 2.11.1 Accuracy: 
To study the accuracy, 10 tablets were 
weighed and powered. Analysis of the same was 
carried out. Recovery studies were carried out by 
standard addition method by adding the known 
amount of MET and GPZ separately to the reanalyzed 
sample at three different concentration levels i.e. 
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50%, 100%, and 150% of assay concentration and 
percent recoveries were calculated. 1 ml of the sample 
solution was pipetted out and transferred to three 10 
ml volumetric flask separately along with this 0.5, 1, 
1.5 ml of aliquots from the stock solution of MET and 
GPZ. All the solutions were filtered through 0.45 μm 
Nylon-66 filter and injected into HPLC system. Peak 
areas were recorded for all the peaks. 
2.11.2 Precision : 
Demonstrate the method precision by 
preparing 6 samples (sample preparation) as per the 
test method representing a single batch were applied 
in triplicate and injected this sample preparation, but 
before diluent, placebo, and standard solution in six 
replicates injected in HPLC system. Determine the 
assay of these samples and evaluate the precision of 
the method by computing the % RSD of the assay 
results.  
2. 11.3 Linearity and Range  
The concentration ranges; 1, 2, 3, 4, 5 μg/mL 
for GPZ and 100,200,300,400,500 μg/mL for MET 
were selected as linearity range. 
2.11.4 Ruggedness : 
The studies were carried out for two 
different parameters.  
a) Intra-day and Inter-day precision: The samples 
were analyzed at different times on same day and on 
different days. The percent of labeled claim was 
calculated and the results are shown in table 4.5  
b) Different Analyst: The samples were analyzed by 
three different analysts by the proposed method. The 
results are shown in table 4.6  
2.11.5 Forced degradation study:  
For deciding that whether the analytical 
method for the assay was stability indicating, tablets 
of MET and GPZ were subjected to various stress 
conditions to conduct forced degradation studies. 
Stress studies were carried out under the conditions of 
acid/base hydrolysis, oxidation, photolytic and 
thermal degradation in accordance with ICH Q1A 
(R2). Several trials with different severity of each 
stressed condition were conducted, so that upto 10-
30% degradation was achieved.  
 
                           Area of unstressed –Area of stressed  
% Degradation = -------------------------------------------×100  
                              Area of unstressed  
 
Acid degradation: Tablets were crushed to fine 
powder and powder equivalent to 500 mg of MET 
and 5.0 mg of GPZ was taken into 250 mL round 
bottom flask. 20 mL of 0.1 N HCL was added to the 
flask and refluxed on heating mantle for 45min at 100 
ºC.  
Basic degradation: Tablets were crushed and powder 
equivalent to 500 mg of MET and 5mg of GPZ was 
taken into 250 ml round bottom flask. 20 mL of 
0.01N NaOH was added to the flask and refluxed on 
heating mantle for 2 hr at 100 ºC.  
 
Oxidative/ peroxide degradation: Tablets were 
crushed and powder equivalent to 500 mg of MET 
and 5mg of GPZ was taken into 250 mL round 
bottom flask. 20 mL of 3% H2O2 was added flask 
and refluxed on heating mantle for 30 min at 100ºC.  
2.11.2 Thermal degradation:  Tablets were crushed 
and powder equivalent to 500 mg of MET and 5mg of 
GPZ was taken into 250 mL round bottom flask. 
Degradation was achived by heating sample at 105ºC.  
2.11.3 Photo degradation: studies were carried out 
on fine Tablet powder.In a petri plate 1mm layer was 
applied and exposed to direct UV radiation for 24 
hours in U.V chamber. The withdrawn samples were 
dissolved and then diluted with mobile phase as per 
sample preparation. 
2.11.4 Robustness: The Robustness of the method 
was evaluated by changing the flow rate by ± 10%, by 
changing the column oven temperature by ± 5°C, by 
changing the wavelength by ± 2nm, by changing the 
organic content of mobile phase by 2% absolute, by 
changing the pH by ± 0.1, system suitability was done 
for each condition. 
 
3 Results and Discussion                                            
3.1 Optimization of Chromatographic Condition 
for Estimation of Drug 
Column: Inertsil C8, 4.6 × 250mm, 5μm 
Flow Rate: 1.0 ml/min 
Wavelength: 222 nm 
Injection volume: 20μl 
Column Temperature: Ambient 
Run Time: 12 minutes 
Mobile Phas: Acetonitrile: Water (70:30)+Tea1 drop 
The result was shown in the Fig 4. 
After establishing the chromatographic 
conditions, Mix standard and marketed preparation 
were prepared and analysed by following procedure 
described under experimental work. It gave accurate, 
reliable results and was extended for estimation of 
drugs in marketed tablet formulation. % recovery of 
tablet formulation containing MET (500mg) and GPZ 
(5mg) was found to be 99.63 and 99.34 with % RSD, 
0.2446 and 0.79 respectively. Linearity was shown & 
the R2 value was found to be 0.999 for MET and 
0.999 for GPZ. The result show that an excellent 
correlation exists between concentration and mean 
peak areas within the concentration range. From the 
studies carried out and result obtained the proposed 
methods are compared in terms of statistical data, 
ease of application and reliability. Thus the method 
developed is accurate, precise, specific, & linear 
hence it can be said that, RP-HPLC is the most 
sensitive, accurate, precise and reproducible among 
all methods.  
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Fig 3: Overlain Spectra of MET & GPZ
 
      Fig 4: Chromatogram of MET and GPZ 
 
Fig 5: Chromatogram for Laboratory mixture of MET and GPZ showing retention time for MET 
3.3333 min, GPZ 4.4167 min 
 
Fig 6: Chromatogram for Marketed Formulation of MET and GPZ showing retentiontime for MET 
3.3231 min, GPZ 4.4231 min. 
 
Fig 7: Calibration curve of MET 
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Fig 8: Calibration curve of GPZ 
 
Table 1: System Suitability For MET 
Sr. No. 
 
Area 
Reproducibility 
 
Retention 
Time 
 
Tailing Factor 
(Asymmetry) 
Theoretical 
Plates 
 
Resolution 
 
1 17594.1281 
 
3.3923 
 
1.813 
 
8872.4 
 
0.0000 
 
2 17515.1131 
 
3.4274 
 
1.790 
 
8912.3 
 
- 
3 17711.1391 
 
3.3892 
 
1.821 
 
8862.34 
 
- 
4 17425.1591 
 
3.4113 
 
1.822 
 
8772.6 
 
- 
5 17615.1191 
 
3.4133 
 
1.783 
 
8872.3 
 
- 
Mean 
 
17572.13 
 
3.4067 
 
1.8058 
 
8858.388 
 
- 
% RSD 
 
0.6 
 
0.46 
 
1.002 
 
0.58 
 
- 
Table 2: System Suitability for GPZ 
 Sr. No. Area 
Reproducibility 
Retention 
Time 
Tailing Factor 
(Asymmetry) 
Theoretical 
Plates 
 Resolution  
1  659.1344  4.5127  1.4167  6084.6  5.1002  
2  658.3263  4.4477  1.5112  6184.6  5.0004  
3  656.3421  4.4267  1.3911  6084.7  4.9001  
4  657.2233  4.3967  1.4147  6074.4  5.0122  
5  649.2312  4.4167  1.4127  6084.6  5.0120  
Mean  656.0515  4.4401  1.4162  6102.58  5.0049  
% RSD  0.6  1.00  0.73  0.08  1.5  
 
Force Degradation Studies:  
Fig 9: Chromatogram of Acid degradation 
 Figure 10: Chromatogram of base degradation 
 
Figure 11: Chromatogram of oxidative degradation 
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Figure 12: Chromatogram of heat degradation 
 
Figure 13: Chromatogram of Photodegradation 
 
Table 3: Summary of force degradation of MET 
Condition  % Assay of MET  % Degradation  
Control sample  98.44  -  
Acid degradation  95.53  2.91  
Base degradation  87.67  10.77  
Oxidative degradation  91.2  7.24  
Thermal Degradation  91.85  6.59  
Photolytic Degradation  97.44  1.00  
 
Table 4: Summary of force degradation of GPZ 
Condition  % Assay of GPZ  % Degradation  
Control sample  99.28  -  
Acid degradation  98.58  0.7  
Base degradation  98.78  0.5  
Oxidative degradation  73.28  26  
Thermal Degradation  99.26  -nill-  
Photolytic 
Degradation  
99.24  -nill-  
 
4. Conclusion 
The developed stability indicating assay 
method was found to be simple, accurate, sensitive, 
precise, specific and rapid. Results obtained in 
validation exercise were fulfilling the acceptance 
criteria. This method can be applied for routine 
quantitative and qualitative analysis of MET and GPZ 
in bulk and pharmaceutical formulations like tablets. 
This method was also used to check quality of 
product after different storage condition and when 
stress degradation is carried out. 
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